New Targets to Improve Patient Outcomes in MZL and FL

home / insights / new-targets-to-improve-patient-outcomes-in-mzl-and-fl

Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.